Antibody, Gene Editing, Gene Therapy and In-Vivo

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Antibody

Gene Editing

Gene Therapy

In-Vivo

American Society of Hematology, Dec. 5-8

The Pharma Data

DECEMBER 11, 2020

of Children’s Hospital at TriStar Centennial in Nashville, Tennessee, and colleagues found that gene editing using CRISPR-Cas9 is safe and feasible and can provide clinical benefit to patients with sickle cell disease and transfusion-dependent ß-thalassemia. In one study, Haydar Frangoul, M.D., Abstract No.

Gene Editing

Gene Editing Gene Gene Therapy In-Vivo

Necessity Is the Mother of Innovation: Key Trends and Predictions from Biotech Showcase Digital After an Unprecedented Year That Drove Momentous Changes in Healthcare

Pharma Marketing Network

JANUARY 20, 2021

Perhaps this omission is because the systemically administered vaccines are unable to stimulate robust immune responses in the mucosae, despite generating systemic neutralizing antibody (and possibly T cell) responses.

Vaccination

Vaccination Vaccine In-Vivo Genetics

Webinars

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

MORE WEBINARS

Clinical Research Informer

American Society of Hematology, Dec. 5-8

Necessity Is the Mother of Innovation: Key Trends and Predictions from Biotech Showcase Digital After an Unprecedented Year That Drove Momentous Changes in Healthcare

Webinars

Stay Connected